AVTECH announced LATAM is pausing its use of ClearPath for its short-haul fleet to benchmark against...
*Q2e top line flat q-o-q, EBITDA of NOK 3m * Pricer transition a temporary drag, offset by Vusion mo...
Redeye comments on the disappointing news that Ascelia has received a CRL from the FDA for Orviglanc...
* Additional clinical data and product documentation requested * Urgent FDA meeting to discuss next ...
Endomines reported today that its gold production amounted to 147.
Germany's only multi-product equity-release platform.
Serieförvärvarens brokiga historik sätter prägel på dagens värdering.
*Solid letting activity, but timing/impact uncertain *Lower interest rate assumptions and SBBs drive...
Redeye returns with an update on AlzeCure following the landmark USD2.
Redeye is positive about Renaparin’s five-year follow-up data.
Duell's Q3 report beat our and Duell's own expectations widely.
After the recent announcements of a divestment and implementation of additional efficiency measures ...
* Q2e: 1% organic growth and 4% EBITA margin * Limited estimate changes * Trading at NTM EV/EBITA of...
We believe Q2 has had a better set-up compared to prior quarters as both BD and Wound Management rev...
* Market conditions remain soft * We lower '26e-'27e adj.
We expect Lassila & Tikanoja (L&T) to face pressure from a rise in diesel and gate prices in Q2.
Cereno Scientific has reported a SEK60m capital raise through a directed share issue of c 11.
Following the capital increase and the new mid-term outlook presented at its CMD, OHB is in our view...
* Renewed SEK 74m order with EU NATO customer (Ovzon-3 related) * 100% SATCOM (5-months); deliveries...
SciBase announced this morning that it has submitted a 510(k) premarket notification to the FDA seek...
